Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338049 · ClinicalTrials.gov registry record · NA
All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules
A NA study of Lung Cancer, sponsored by Veran Medical Technologies.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT03338049: Completed NA study of Lung Cancer, sponsored by Veran Medical Technologies.
NCT03338049 is a NA study of Lung Cancer that has completed, run by Veran Medical Technologies. The registered enrollment target is 150 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03338049, a NA study of Lung Cancer, has completed, sponsored by Veran Medical Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multi-center, non-randomized, single-arm, prospective trial to evaluate a staged sampling methodology designed to maximize the diagnostic yield of lung biopsy in a single procedure setting.
Primary Outcome
Diagnostic yield associated with either EMN-bronchoscopy or EMN-TTNA
Conditions Studied
Interventions
- DEVICE Veran System
Study Locations (9)
North Carolina
- University of North Carolina Medical Center - Chapel Hill
- Duke University Hospital - Durham
Arizona
- Banner University Medical Center - Phoenix - Phoenix
Georgia
- Grady Memorial Hospital - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
Missouri
- Washington University Medical Center - St Louis
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
South Carolina
- Medical University of South Carolina Medical Center - Charleston
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2019-12-01 |
| Phase | NA |
What the finished NCT03338049 record still lists
NCT03338049 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Veran System is the first listed.
NCT03338049 lists 9 locations in 8 states (North Carolina, Arizona, Georgia).
Frequently Asked Questions
What is clinical trial NCT03338049 about?
NCT03338049 is a clinical study titled "All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules". This is a multi-center, non-randomized, single-arm, prospective trial to evaluate a staged sampling methodology designed to maximize the diagnostic yield of lung biopsy in a single procedure setting.
What is the current status of trial NCT03338049?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2018-02-14. Estimated completion is 2019-12-01.
What conditions does trial NCT03338049 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT03338049?
The interventions under investigation include: Veran System (DEVICE).
Who is sponsoring clinical trial NCT03338049?
This trial is sponsored by Veran Medical Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03338049 being conducted?
This trial has 9 study locations across Arizona, Georgia, Maryland, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03338049's enrollment target sits among peer trials
150 148th of 409 higher than 260 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI